Payment overview · 2025
General Payments
$1,342.61
64 reported records · 20 companies
Healthcare provider profile · identity verified
Michael Ryder, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MEDFORD, NY · NPI 1659598589
Verified facts
What the public records show
CMS Open Payments records show Michael Ryder, D.O. received $1,342.61 in general payments during 2025 across 64 reported records.
Axsome Therapeutics, Inc. accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 362 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $182.13 | 13.6% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $168.45 | 12.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.49 | 10.2% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $116.76 | 8.7% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $77.60 | 5.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.62 | 5.3% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $69.45 | 5.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.81 | 4.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $60.06 | 4.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.29 | 4.3% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $54.90 | 4.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.54 | 3.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.01 | 3.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.85 | 3.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.25 | 3.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.73 | 2.0% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $23.94 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.18 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.93 | 1.4% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $13.62 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,342.61 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $195.18 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $182.13 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $86.23 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $85.81 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $85.81 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $77.60 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $69.45 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $60.06 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.29 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.29 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $54.90 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $50.68 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.54 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 362 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
362 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 637 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 132 |
| Potassium Chloride | Potassium Chloride | 387 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 375 | 124 |
| Eliquis | Apixaban | 362 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 348 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 312 | 108 |
| Losartan Potassium | Losartan Potassium | 306 | 98 |
| Furosemide | Furosemide | 287 | 81 |
| Gabapentin | Gabapentin | 261 | 79 |
| Simvastatin | Simvastatin | 250 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 243 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 73 |
| Mirtazapine | Mirtazapine | 205 | 62 |
| Lisinopril | Lisinopril | 200 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 67 |
| Metformin Hcl | Metformin Hcl | 188 | 58 |
| Omeprazole | Omeprazole | 188 | 61 |
| Donepezil Hcl | Donepezil Hcl | 164 | 42 |
| Trazodone Hcl | Trazodone Hcl | 158 | 33 |
| Torsemide | Torsemide | 155 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 143 | 50 |
| Memantine Hcl | Memantine Hcl | 140 | 32 |
| Spironolactone | Spironolactone | 130 | 44 |
| Prednisone | Prednisone | 129 | 80 |
| Carvedilol | Carvedilol | 127 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 43 |
| Alprazolam | Alprazolam | 124 | 59 |
| Allopurinol | Allopurinol | 117 | 36 |
| Ozempic | Semaglutide | 115 | 22 |
| Sertraline Hcl | Sertraline Hcl | 112 | 26 |
| Famotidine | Famotidine | 108 | 37 |
| Montelukast Sodium | Montelukast Sodium | 107 | 30 |
| Buspirone Hcl | Buspirone Hcl | 105 | 28 |
| Nystatin | Nystatin | 102 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 26 |
| Sodium Chloride | 0.9 % Sodium Chloride | 97 | 24 |
| Synthroid | Levothyroxine Sodium | 95 | 24 |
| Warfarin Sodium | Warfarin Sodium | 95 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 48 |
| Entresto | Sacubitril/Valsartan | 89 | 16 |
| Ezetimibe | Ezetimibe | 84 | 30 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 79 | 31 |
| Xarelto | Rivaroxaban | 77 | 14 |
| Farxiga | Dapagliflozin Propanediol | 73 | 14 |
| Latanoprost | Latanoprost | 68 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 22 |
| Santyl | Collagenase Clostridium Hist. | 65 | 20 |
| Jardiance | Empagliflozin | 63 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 38 |
| Levetiracetam | Levetiracetam | 58 | 13 |
| Linzess | Linaclotide | 58 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 13 |
| Januvia | Sitagliptin Phosphate | 56 | 11 |
| Cephalexin | Cephalexin | 54 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 21 |
| Vancomycin Hcl | Vancomycin Hcl | 54 | 14 |
| Finasteride | Finasteride | 52 | 20 |
| Tramadol Hcl | Tramadol Hcl | 52 | 17 |
| Daptomycin | Daptomycin | 51 | suppressed |
| Atenolol | Atenolol | 50 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 16 |
| Azelastine Hcl | Azelastine Hcl | 49 | 31 |
| Ramipril | Ramipril | 48 | 17 |
| Meloxicam | Meloxicam | 47 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Telmisartan | Telmisartan | 46 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 38 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 20 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 45 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 12 |
| Midodrine Hcl | Midodrine Hcl | 43 | 14 |
| Sucralfate | Sucralfate | 43 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 42 | 19 |
| Azithromycin | Azithromycin | 42 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 17 |
| Levofloxacin | Levofloxacin | 41 | 38 |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Budesonide | Budesonide | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 13 |
| Glimepiride | Glimepiride | 37 | 12 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | 12 |
| Movantik | Naloxegol Oxalate | 35 | suppressed |
| Nyamyc | Nystatin | 35 | 12 |
| Pregabalin | Pregabalin | 34 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ertapenem | Ertapenem Sodium | 32 | 19 |
| Folic Acid | Folic Acid | 32 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 19 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Erythromycin | Erythromycin Base | 25 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 22 |
| Dextrose In Water | Dextrose 5 % In Water | 24 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Procrit | Epoetin Alfa | 23 | suppressed |
| Generlac | Lactulose | 22 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | 11 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Glipizide | Glipizide | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Admelog | Insulin Lispro | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | 11 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,342.61 · 64 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, BREZTRI, DUPIXENT, ELIQUIS, FARXIGA, IBSRELA, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Natroba, OFEV, OTEZLA, Ohtuvayre, REPATHA, REXULTI, Spinosad, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, WAKIX, XIFAXAN, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error